· Summary
· Drug effects
· PD
· PK
· PC
Pharmacodynamic (PD) |
Complementary and synergistic -> ↓dose -> ↓side effects |
Pharmacokinetic (PK) |
Synergy -> ↓dose -> ↓accumulation No interference |
Pharmaceutics (PC) |
No incompatibility |
|
Sevoflurane (SF) |
Fentanyl (F) |
Amnesia |
MAC 0.25 |
Unreliable even at high Ce |
Hypnosis |
MAC 0.3 |
|
Immobility |
MAC 1 |
No |
Analgesia |
No |
Yes |
CVS side effects |
↓HR, ↓contractility, ↓SVR, ↓mAP |
↓SNS output -> ↓HR, ↓SVR, ↓mAP |
Resp side effects |
↑RR, ↓TV |
↓RR, ↓TV |
Other |
PONV ↑Uterine blood flow +/- PPH ↑Cerebral blood flow +/- ICP |
PONV Sedation |
Complementary |
· SF: anaesthesia · F: analgesia |
|||||||||||||||
Synergistic |
· Combined effect exceeds sum of individual effects · Represented by isobologram (or response surface) · Mechanism: ? F reduces nociceptive activation of ascending reticular activating system (ARAS)
|
|||||||||||||||
Implications of synergism |
· ↓SF % for hypnosis and immobility · ↓MAC standard deviation -> ↓variability · ↓SF side effects · ↓Need for paralysis |
|||||||||||||||
Quantification of interaction |
https://www.ncbi.nlm.nih.gov/pubmed/9447851 https://www.ncbi.nlm.nih.gov/pubmed/?term=fentanyl+sevoflurane+somatic+1999
|
Lack of interference |
· Plasma protein binding sites: o Fentanyl to AAG > albumin o Sevoflurane uptake to proteins, lipids, RBCs · Metabolism: o SF -> liver CYP2E1 (only 2-5%) o F -> liver CYP3A4 (almost 100%) · Excretion: o SF via lungs o F metabolites via urine |
Implications of synergism |
· For a given desired effect, ↓[SF] and ↓[F] · ↓compartmental concentrations · ↓total dose, ↓accumulation · ↓time to emergence (since MAC awake less affected) |
Compatibility |
None: F intravenous, SF inhaled |
Efficiency |
Synergism -> ↓total dose -> ↓cost |
Feedback welcome at ketaminenightmares@gmail.com